Linked Life Data

19579422

Source:http://linkedlifedata.com/resource/pubmed/id/19579422

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
206
pubmed:dateCreated
2009-7-7
pubmed:abstractText
Type 1 diabetes currently affects 15,000 patients in Switzerland with a rising incidence worldwide. Pancreas or islet of Langerhans transplantation are alternatives to intensive insulin treatment, which decreases long-term complications at the cost of an increase of severe hyoglycemia. Pancreas transplantation, indicated mainly to diabetic patients with simultaneous kidney transplantation, has a high success rate, but is accompanied by high morbidity due to general surgery. Islet transplantation, a cell-therapy for type 1 diabetes, is in full development. It is mainly indicated as islet transplant alone in patients suffering from brittle diabetes, and is associated with a very low risk due to minimally invasive technique, but a lower rate of long-term success. New potential sources of beta cell replacement are beta-cell lines, stem cells and xenotransplantation.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1660-9379
pubmed:author
pubmed:issnType
Print
pubmed:day
3
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1266-70, 1272
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
[Pancreas and islets of Langerhans transplantation: current status in 2009 and perspectives].
pubmed:affiliation
Laboratoire d'isolement et de transplantation cellulaire CMU, 1211 Genève 4.
pubmed:publicationType
Journal Article, English Abstract